Personalized nutrition support available “on demand” to patients and caregivers HOUSTON – April 16, 2020 – The Kidney Cancer Association (KCA) is pleased to announce its partnership with Savor Health® to bring Ina®, The Intelligent…

Young Investigator and Advanced Discovery Awards will advance kidney cancer research HOUSTON – March 18, 2020 – The Kidney Cancer Association (KCA) is pleased to announce applications for both its Young Investigator Awards (YIAs) and…

A total of $1.3 million awarded to advance new treatments for kidney cancer HOUSTON – September 16, 2019 – The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards…

HOUSTON – April 16, 2019 – The Kidney Cancer Association (KCA) is pleased to announce its Board of Directors recently approved $1.3 million in new grant funding to advance early detection and new treatments for…

HOUSTON – March 19, 2019 – The Kidney Cancer Association (KCA) is pleased to announce that Kendall Monroe has joined the organization as its first Chief Advancement Officer (CAO). Monroe brings more than a decade…

Four years ago, Joanne Romero, who lives in Texas, was diagnosed with stage 4 kidney cancer when she was 26 weeks pregnant. Despite her challenges, Joanne remains positive and hopes her story serves as an inspiration to others. 

In this article, Dr. Marc-Oliver Grimm provides an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session.

Use of broad-spectrum antibiotics 30 days before starting an immune checkpoint inhibitor was associated with a dramatic reduction in cancer patients’ survival, a prospective study found.

The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to immune checkpoint inhibitors and novel combinations.

While clinical outcomes may be comparable in patients with metastatic renal cell carcinoma (RCC) who are treated with full vs reduced dose of cabozantinib, reduced dose may not be associated with decreased adverse events.